Wegovy vs Zepbound: The Definitive Comparison of FDA-Approved Weight Loss Medications

The primary question most patients ask about Wegovy and Zepbound is straightforward: which one produces more weight loss? The clinical trial data provides a clear answer, though individual results will always vary.

Wegovy (semaglutide 2.4 mg) was evaluated in the STEP clinical trial program. In the pivotal STEP 1 trial, 1,961 adults with obesity or overweight received either Wegovy or placebo for 68 weeks alongside lifestyle intervention. Participants on Wegovy lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. Approximately 32% of Wegovy patients achieved weight loss of 20% or more, and 12% lost 25% or more of their starting weight.

Zepbound (tirzepatide) was studied in the SURMOUNT trial program. In SURMOUNT-1, 2,539 adults received tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks. At the highest dose (15 mg), average weight loss was 22.5% of body weight — roughly one-quarter of starting weight. Even the lowest dose (5 mg) produced 15.0% weight loss, comparable to maximum-dose Wegovy. At 15 mg, 63% of participants lost at least 20% of body weight, and 36% lost at least 25%.

While these are not head-to-head comparisons (no trial has directly compared Wegovy 2.4 mg vs. Zepbound 15 mg), the consistency of the data across studies makes the comparison meaningful. Tirzepatide produces approximately 50% more weight loss than semaglutide at their respective maximum approved doses.

The superior weight loss seen with Zepbound stems from its unique dual-receptor mechanism. Understanding the pharmacological differences helps explain why these two medications, both given as weekly injections, produce meaningfully different outcomes.

Wegovy contains semaglutide, which acts exclusively on GLP-1 receptors. This single-receptor approach produces powerful appetite suppression, slowed gastric emptying, and improved insulin dynamics. The STEP trial program demonstrated that these effects, while targeting only one hormonal pathway, are sufficient to produce clinically significant weight loss in most patients.

Zepbound contains tirzepatide, which simultaneously activates both GIP and GLP-1 receptors. The GIP component adds metabolic effects that complement and amplify the GLP-1 pathway. GIP receptor activation improves insulin sensitivity in fat tissue, enhances lipid metabolism, and may provide additional appetite-regulating signals in the brain that operate through different neurological circuits than GLP-1.

Emerging research suggests the dual mechanism may also produce differences in body composition. Preliminary analyses from SURMOUNT trials indicate that tirzepatide patients may preserve a slightly higher proportion of lean muscle mass relative to fat mass during weight loss. This is a critical consideration, as muscle loss during rapid weight reduction can negatively impact metabolic rate, functional capacity, and long-term weight maintenance.

Weight loss medications are increasingly evaluated not just for pounds lost, but for their impact on cardiovascular disease — the leading cause of death in patients with obesity. In this arena, Wegovy currently holds a significant evidence advantage.

The SELECT trial, published in 2023, was a landmark cardiovascular outcomes study for semaglutide. Over 17,600 adults with overweight or obesity and established cardiovascular disease (but without diabetes) were randomized to semaglutide 2.4 mg or placebo. Semaglutide reduced the risk of major adverse cardiovascular events (MACE — cardiovascular death, nonfatal heart attack, or nonfatal stroke) by 20% over a median follow-up of 33 months. This led to an expanded FDA indication for Wegovy for cardiovascular risk reduction in March 2024.

Zepbound does not yet have dedicated cardiovascular outcomes data. Eli Lilly's SURPASS-CVOT trial evaluating tirzepatide's cardiovascular effects is ongoing, with results expected in the coming years. However, tirzepatide's metabolic effects — substantial reductions in body weight, blood pressure (6-9 mmHg systolic), triglycerides (19-25%), and inflammatory markers — suggest a favorable cardiovascular profile.

Additionally, Wegovy demonstrated benefits in heart failure. The STEP-HFpEF trial showed that semaglutide significantly improved symptoms, physical limitations, and exercise function in obese patients with heart failure with preserved ejection fraction (HFpEF), a condition with limited treatment options.

Both Wegovy and Zepbound cause gastrointestinal side effects as their primary adverse reactions. These effects are inherent to incretin-based therapies and are generally most pronounced during dose escalation.

Wegovy's side effect data from the STEP program showed: nausea (44% vs. 17% placebo), diarrhea (30% vs. 16%), vomiting (24% vs. 6%), constipation (24% vs. 10%), and abdominal pain (8% vs. 6%). The relatively high incidence of nausea and vomiting is notable, though these effects are typically transient and most common during the dose-escalation phase. The discontinuation rate due to adverse events was 7% for semaglutide vs. 3.1% for placebo in STEP 1.

Zepbound's SURMOUNT data showed generally lower GI side effect rates: nausea (24-33% depending on dose), diarrhea (18-25%), vomiting (6-12%), constipation (12-17%), and decreased appetite (10-14%). Discontinuation due to adverse events ranged from 4.3% to 7.1% across doses. The lower nausea and vomiting rates are potentially significant for patients who are particularly sensitive to GI disturbances.

Both medications share class-wide safety considerations: boxed warnings for medullary thyroid carcinoma risk (based on rodent studies), contraindication in patients with MEN 2 syndrome, and warnings regarding pancreatitis and gallbladder disease. Acute kidney injury has been reported rarely with both, typically in the context of severe dehydration from GI side effects.

For patients pursuing weight loss without diabetes, cost is often the deciding factor between Wegovy and Zepbound — especially since insurance coverage for anti-obesity medications remains inconsistent.

Wegovy's list price is approximately $1,350 per month. Novo Nordisk has offered savings programs, but supply constraints have periodically limited availability. Insurance coverage for Wegovy has improved but is far from universal. As of 2025, roughly 40-50% of commercial plans offer some coverage for anti-obesity medications, though prior authorization requirements, step therapy, and quantity limits are common. Medicare coverage for weight loss drugs expanded in 2026 following legislative action.

Zepbound is priced at approximately $1,060 per month — roughly $290 less than Wegovy at list price. Eli Lilly has been aggressive with patient access programs, including direct-to-consumer pricing through LillyDirect at reduced rates for cash-pay patients. Insurance coverage patterns for Zepbound are similar to Wegovy, with the added complexity that it launched more recently and may not yet be on all formularies.

At Weight Method, we remove the insurance uncertainty entirely. Semaglutide (the active ingredient in Wegovy) is available at $297 per month, and tirzepatide (the active ingredient in Zepbound) at $349 per month. Both include clinician evaluation, personalized dosing, and ongoing medical oversight. For patients weighing the 50% greater average weight loss of tirzepatide against the $52 monthly price difference, the value proposition is clear — and both options are a fraction of brand-name pricing.